Artificial intelligence is attracting serious investment across Southeast Asia. Startups are using it to automate business processes, develop new products, and solve problems that once required large engineering teams.
Healthcare should be a natural beneficiary. AI can assist with clinical documentation, diagnostics, administrative tasks, and remote care. Yet the region’s healthtech funding numbers tell a different story.
According to e27’s analysis of Tracxn data, Southeast Asian healthtech funding declined from US$397 million in 2023 to US$59.7 million in 2025, with US$35.7 million recorded in 2026 through July 9.
Meanwhile, AI and SaaS have attracted a growing share of regional technology investment.
The contradiction raises an important question: If healthcare AI has so much potential, why is attracting investment still difficult for healthtech founders?
I believe the answer lies less in the technology itself and more in how healthcare startups demonstrate commercial viability.
Innovation is growing, but investor expectations have changedDuring the pandemic, digital health gained urgency as hospitals, patients, and healthcare organisations sought alternatives to traditional care delivery.
Telemedicine, online consultations, digital prescriptions, and remote monitoring attracted greater attention. For investors, accelerating digital adoption created compelling opportunities.
But demand for healthcare technology does not automatically translate into sustainable startup revenue.
Today, a healthtech company may demonstrate impressive technology and still struggle to answer basic commercial questions.
Who pays for the product? How long does it take to acquire a healthcare customer? What evidence supports its clinical value? Can it generate recurring revenue without depending on continuous funding?
These questions have always mattered. In a more selective investment environment, they become harder to avoid.
The shift is visible across the broader startup ecosystem. e27’s September 2026 funding coverage reported that Southeast Asian startups raised US$7.25 billion in the first half of 2026, while equity deal volume declined year on year.
Capital is available, but not every startup is benefiting equally.
Healthcare AI has a commercialisation problem
Consider a startup developing an AI-powered medical documentation assistant.
Its demonstration might show that clinicians can generate consultation notes faster. The model could perform well in controlled testing, and early users might respond positively.
But a hospital considering deployment will evaluate much more than transcription accuracy.
It may need assurance that generated notes are clinically appropriate, patient information is protected, existing records remain consistent, and doctors can review and correct outputs.
Also Read: Why Southeast Asia’s next healthtech winners will be built around healthcare workflows, not just AI
The hospital must also justify the expense.
Will the technology reduce administrative work? Improve documentation quality? Release clinician capacity? Or simply introduce another software subscription?
The gap between demonstrating technical capability and proving measurable operational value can be substantial.
This is why I would encourage healthcare AI founders to start with a specific business or clinical problem rather than the capabilities of their chosen model.
An impressive AI demonstration may attract attention. Evidence that it creates sustainable value gives customers a stronger reason to buy.
Hospital pilots are not the same as product-market fit
A successful pilot is an important milestone, but it can create a misleading sense of progress.
Suppose a digital health startup secures pilots with three hospitals.
Each deployment requires different integrations, security reviews, staff training, and adjustments to existing processes. The startup delivers the projects successfully, but implementation costs remain high.
If every new hospital requires extensive customisation, the business may behave more like a consulting company than a scalable software provider.
For founders, this creates a difficult trade-off.
Customisation can help win early customers, but excessive customer-specific engineering can weaken margins and delay expansion.
The better approach is to distinguish between capabilities that should remain standard across customers and those that genuinely require local adaptation.
It also helps to track the economics of each deployment: implementation cost, time to launch, recurring revenue, support requirements, and customer retention.
A startup with five paying hospitals and repeatable deployment processes may have a stronger commercial foundation than one with dozens of unpaid pilots.
Southeast Asia is not one healthcare market
Regional expansion presents another challenge.
A healthtech company succeeding in Singapore may see Indonesia, Malaysia, Thailand, or Vietnam as natural growth opportunities.
However, healthcare systems differ in financing, provider structures, privacy obligations, clinical practices, and digital maturity.
A business model built around private hospital purchasing may not transfer easily to a market where public-sector procurement plays a larger role.
Similarly, a product that relies on established electronic health record integrations could face additional implementation work in less connected environments.
The World Health Organisation’s Global Strategy on Digital Health 2020–2027 recognises the importance of coordinating financial, organisational, human, and technological resources to support digital healthcare.
For startups, regional scalability therefore requires more than translation and marketing.
It means identifying which parts of a product can be reused, where local adaptation is unavoidable, and whether expansion improves or weakens the underlying economics.
Also Read: Vietnam’s healthtech boom has a talent problem nobody is talking about
What should healthtech founders prove before raising capital?
If I were assessing a healthtech startup’s readiness for its next growth stage, I would focus on four questions.
- First, is there a paying customer with a recurring problem? Healthcare challenges can be widespread without creating an immediately viable market. Founders must identify who experiences the problem, who controls the budget, and why the solution is worth purchasing.
- Second, can the startup demonstrate measurable value? Reduced administrative time, faster deployment, improved care coordination, or fewer avoidable manual tasks provide a more persuasive business case than feature counts alone.
- Third, can the product scale without proportional implementation costs? Reusable architecture, dependable integrations, and repeatable onboarding become especially important when selling to multiple healthcare organisations.
- Finally, can the business earn trust? Healthcare customers need confidence in data governance, reliability, clinical oversight, and the company’s ability to support them beyond the initial pilot.
None of these factors guarantees investment. Together, however, they help distinguish a promising technical concept from a business capable of delivering lasting value.
The next healthtech opportunity is bigger than AI
Southeast Asia’s healthcare challenges have not disappeared simply because funding has become more selective.
Ageing populations, chronic disease management, administrative inefficiency, and unequal access to services continue to create demand for better healthcare delivery.
AI offers valuable tools to address parts of these challenges. But founders should resist treating AI adoption as a business model in itself.
The companies that emerge stronger from this funding cycle may be those that build around genuine customer demand, measurable outcomes, dependable technology, and sustainable economics.
For Southeast Asia’s healthtech ecosystem, the next breakthrough may not be another impressive AI application.
It may be a healthcare technology business that proves innovation can scale commercially while delivering value to the organisations and people it serves.
—
Editor’s note: e27 aims to foster thought leadership by publishing views from the community. You can also share your perspective by submitting an article, video, podcast, or infographic.
The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of e27.
Join us on WhatsApp, Instagram, Facebook, X, and LinkedIn to stay connected.
The post Why Southeast Asia’s healthtech startups struggle to attract investment despite the AI boom appeared first on e27.
Artificial intelligence is attracting serious investment across Southeast Asia. Startups are using it to automate business processes, develop new products, and solve problems that once required large engineering teams.
Healthcare should be a natural beneficiary. AI can assist with clinical documentation, diagnostics, administrative tasks, and remote care. Yet the region’s healthtech funding numbers tell a different story.
According to e27’s analysis of Tracxn data, Southeast Asian healthtech funding declined from US$397 million in 2023 to US$59.7 million in 2025, with US$35.7 million recorded in 2026 through July 9.
Meanwhile, AI and SaaS have attracted a growing share of regional technology investment.
The contradiction raises an important question: If healthcare AI has so much potential, why is attracting investment still difficult for healthtech founders?
I believe the answer lies less in the technology itself and more in how healthcare startups demonstrate commercial viability.
Innovation is growing, but investor expectations have changedDuring the pandemic, digital health gained urgency as hospitals, patients, and healthcare organisations sought alternatives to traditional care delivery.
Telemedicine, online consultations, digital prescriptions, and remote monitoring attracted greater attention. For investors, accelerating digital adoption created compelling opportunities.
But demand for healthcare technology does not automatically translate into sustainable startup revenue.
Today, a healthtech company may demonstrate impressive technology and still struggle to answer basic commercial questions.
Who pays for the product? How long does it take to acquire a healthcare customer? What evidence supports its clinical value? Can it generate recurring revenue without depending on continuous funding?
These questions have always mattered. In a more selective investment environment, they become harder to avoid.
The shift is visible across the broader startup ecosystem. e27’s September 2026 funding coverage reported that Southeast Asian startups raised US$7.25 billion in the first half of 2026, while equity deal volume declined year on year.
Capital is available, but not every startup is benefiting equally.
Healthcare AI has a commercialisation problem
Consider a startup developing an AI-powered medical documentation assistant.
Its demonstration might show that clinicians can generate consultation notes faster. The model could perform well in controlled testing, and early users might respond positively.
But a hospital considering deployment will evaluate much more than transcription accuracy.
It may need assurance that generated notes are clinically appropriate, patient information is protected, existing records remain consistent, and doctors can review and correct outputs.
Also Read: Why Southeast Asia’s next healthtech winners will be built around healthcare workflows, not just AI
The hospital must also justify the expense.
Will the technology reduce administrative work? Improve documentation quality? Release clinician capacity? Or simply introduce another software subscription?
The gap between demonstrating technical capability and proving measurable operational value can be substantial.
This is why I would encourage healthcare AI founders to start with a specific business or clinical problem rather than the capabilities of their chosen model.
An impressive AI demonstration may attract attention. Evidence that it creates sustainable value gives customers a stronger reason to buy.
Hospital pilots are not the same as product-market fit
A successful pilot is an important milestone, but it can create a misleading sense of progress.
Suppose a digital health startup secures pilots with three hospitals.
Each deployment requires different integrations, security reviews, staff training, and adjustments to existing processes. The startup delivers the projects successfully, but implementation costs remain high.
If every new hospital requires extensive customisation, the business may behave more like a consulting company than a scalable software provider.
For founders, this creates a difficult trade-off.
Customisation can help win early customers, but excessive customer-specific engineering can weaken margins and delay expansion.
The better approach is to distinguish between capabilities that should remain standard across customers and those that genuinely require local adaptation.
It also helps to track the economics of each deployment: implementation cost, time to launch, recurring revenue, support requirements, and customer retention.
A startup with five paying hospitals and repeatable deployment processes may have a stronger commercial foundation than one with dozens of unpaid pilots.
Southeast Asia is not one healthcare market
Regional expansion presents another challenge.
A healthtech company succeeding in Singapore may see Indonesia, Malaysia, Thailand, or Vietnam as natural growth opportunities.
However, healthcare systems differ in financing, provider structures, privacy obligations, clinical practices, and digital maturity.
A business model built around private hospital purchasing may not transfer easily to a market where public-sector procurement plays a larger role.
Similarly, a product that relies on established electronic health record integrations could face additional implementation work in less connected environments.
The World Health Organisation’s Global Strategy on Digital Health 2020–2027 recognises the importance of coordinating financial, organisational, human, and technological resources to support digital healthcare.
For startups, regional scalability therefore requires more than translation and marketing.
It means identifying which parts of a product can be reused, where local adaptation is unavoidable, and whether expansion improves or weakens the underlying economics.
Also Read: Vietnam’s healthtech boom has a talent problem nobody is talking about
What should healthtech founders prove before raising capital?
If I were assessing a healthtech startup’s readiness for its next growth stage, I would focus on four questions.
- First, is there a paying customer with a recurring problem? Healthcare challenges can be widespread without creating an immediately viable market. Founders must identify who experiences the problem, who controls the budget, and why the solution is worth purchasing.
- Second, can the startup demonstrate measurable value? Reduced administrative time, faster deployment, improved care coordination, or fewer avoidable manual tasks provide a more persuasive business case than feature counts alone.
- Third, can the product scale without proportional implementation costs? Reusable architecture, dependable integrations, and repeatable onboarding become especially important when selling to multiple healthcare organisations.
- Finally, can the business earn trust? Healthcare customers need confidence in data governance, reliability, clinical oversight, and the company’s ability to support them beyond the initial pilot.
None of these factors guarantees investment. Together, however, they help distinguish a promising technical concept from a business capable of delivering lasting value.
The next healthtech opportunity is bigger than AI
Southeast Asia’s healthcare challenges have not disappeared simply because funding has become more selective.
Ageing populations, chronic disease management, administrative inefficiency, and unequal access to services continue to create demand for better healthcare delivery.
AI offers valuable tools to address parts of these challenges. But founders should resist treating AI adoption as a business model in itself.
The companies that emerge stronger from this funding cycle may be those that build around genuine customer demand, measurable outcomes, dependable technology, and sustainable economics.
For Southeast Asia’s healthtech ecosystem, the next breakthrough may not be another impressive AI application.
It may be a healthcare technology business that proves innovation can scale commercially while delivering value to the organisations and people it serves.
—
Editor’s note: e27 aims to foster thought leadership by publishing views from the community. You can also share your perspective by submitting an article, video, podcast, or infographic.
The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of e27.
Join us on WhatsApp, Instagram, Facebook, X, and LinkedIn to stay connected.
The post Why Southeast Asia’s healthtech startups struggle to attract investment despite the AI boom appeared first on e27.
投资人评论
聊判断，不堆黑话登录且账号审核通过后可评论。 立即登录